Upgrade group n=22 de Novo group n=71
P
Heart failure etiology
Chagas, n (%) 16 (72.7%) 13 (18.3%) <0.001*
Idiopathic, n (%) 1 (4.5%) 27 (38.0%) 0.003*
Ischemic, n (%) 1 (4.5%) 14 (19.7%) 0.109*
Age, years, mean (±SD) 62.4 (±13.8) 56.6 (±11.4) 0.080 †
Male gender, n (%) 15 (68.2%) 36 (50.7%) 0.220*
LVEF, mean (±SD) 22.3 (±7.1) 24.4 (±7.6) 0.249†
NYHA class III or IV, n (%) 19 (86.4%) 57 (80.3%) 0.754*
Atrial fibrillation, n (%) 5 (22.7%) 15 (21.1%) 0.999*
QRS > 150ms, n (%) 21 (95.5%) 64 (90.1%) 0.675*
QRS duration, mean (±SD) 158.2 (±14.7) 160.1 (±22.5) 0.636†
non-LBBB, n (%) 1 (4.5%) 5 (7.0%) 0.999*
Myocardial infarction, n (%) 2 (9.1%) 10 (14.1%) 0.725*
Stroke, n (%) 3 (13.6%) 4 (5.6%) 0.350*
Hemoglobin, g/dL median (IQ) 13.0 (11.0 – 13.0) 13.0 (12.0 – 14.0) 0.147‡
Chronic kidney disease, n (%) 8 (36.4%) 17 (23.9%) 0.278*
Diabetes, n (%) 7 (31.8%) 23 (32.4%) 0.999*
CRT-D 14 (63,6%) 29 (40,8%) 0.086*
Medications
ACEI, ARB or ARNI 20 (90.9%) 61 (85.9%) 0.725*
Beta-blocker 21 (95.5%) 65 (91.5%) 0.999*
Spironolactone 18 (81.8%) 63 (88.7%) 0.469*